Serotonin receptors play an important role in regulating mood, sleep, aggression, sociability, stress, mental functions, memory, learning, hunger, vasoconstriction, and body temperature.
These receptors are also known as 5-HT receptors and they are activated by the neurotransmitter Serotonin.
Serotonin (5-HT, 5-Hydroxytryptamine) is an inhibitory neurotransmitter that is linked to feelings of happiness and contentment. When levels of this neurotransmitter are low, symptoms of depression or anxiety may occur, as well as over-eating, irritation, and poor sleep patterns.
Seven different Serotonin receptor subtypes have been identified. They are numbered 5-HT1 through 5-HT7 and they are distributed throughout the body, intestinal tract, and central nervous system.
Ninety percent of the Serotonin found in the body is located in the enterochromaffin cells in the GI tract. Serotonin receptor locations in the gut are used to regulate digestion and intestinal muscle contractions. However, most Serotonin receptor agonist drugs and supplements target the receptors located in the brain which are involved in mood regulation.



- Increases Serotonin levels in the brain
- Enhances mood and alleviates stress
- Improves sleep and regulates appetite
Serotonin Receptors
Related Topics
When Serotonin is released in the brain (or elsewhere in the body), it can bind to Serotonin receptors located on neurons that it comes in contact with.
Depending on the type of receptor it binds to, a different response may occur. There are Serotonin receptor locations in many various parts of the body, and they can have different functions depending on that location.
Serotonin receptors have a number of different functions in the body. This receptor modulates the release of a number of other neurotransmitters, including GABA, glutamate, Dopamine, Acetylcholine, Epinephrine, and Norepinephrine.
It is also involved in modulating the release of certain hormones, including vasopressin, cortisol, oxytocin and prolactin. The activation of Serotonin receptors can also influence mood, anxiety, learning, memory, sleep, and feelings of relaxation and calm.
Serotonin Receptor Modulators: Agonists and Antagonists
As a result of these diverse actions, a number of drugs and supplements are designed to target Serotonin receptors for certain therapeutic effects.
Many drugs prescribed for the treatment of anxiety and depression work by activating these receptors. Drugs for migraine headaches and weight loss supplements may also work by increasing Serotonin receptor activity.
A number of psychedelic drugs, such as LSD and Mescaline, also work by stimulating 5-HT receptors to a very high degree. These compounds are referred to as “serotonin receptor agonists” because they promote a specific physiological response.
In comparison, drugs that block the effects of Serotonin receptors are called “antagonists”. Drugs such as yohimbine, propranolol, and clozapine are Serotonin receptor antagonists for certain subtypes of Serotonin receptors.
Most pharmaceutical agents will only activate specific families of 5-HT receptors, due to biochemical differences in the receptor structures. These are called selective Serotonin receptor agonists; drugs that activate all types are called non-selective agonists.
Effects of Increased Serotonin Activity
There is a lot of research that has gone into cataloging the effects of agonizing or antagonizing certain types of Serotonin receptors. These pathways are quite complex. But generally, we know that increasing levels of Serotonin in the brain can have a relaxing, soothing effect (up to a specific point).
In research studies, higher levels of Serotonin in the brain have been correlated with a reduction in symptoms of depression and anxiety.
Taking a supplement that increases Serotonin activity can improve sleep onset and sleep quality, improve mood, promote appetite suppression and weight loss, alleviate feelings of pain, and reduce migraine occurrence.
How to Boost Serotonin Activity
There are several different ways to increase the activity at Serotonin receptors in the brain.
Doctors may prescribe drugs that can activate these pathways directly, or agents like Selective Serotonin Re-Uptake Inhibitors (SSRIs) that prolong the action of Serotonin once it has been released by a neuron. Examples of SSRIs include Prozac, Zoloft, Paxil, Lexapro, and Celexa.
Another way to affect Serotonin activity levels is by naturally increasing the amount of this neurotransmitter that is available to use in the brain. There is a popular class of Serotonin-boosting supplements designed to achieve this effect.
Two supplements that may increase Serotonin levels are 5-HTP and L-Tryptophan. Both of these are natural compounds that are involved in the synthesis of Serotonin in the brain.
L-Tryptophan and 5-HTP
L-Tryptophan is an amino acid, found in foods such as turkey, chicken, red meats, fish, dairy products, and other high-protein sources. When ingested, some of the L-Tryptophan consumed gets converted into 5-HTP in the liver.
5-HTP (5-Hydroxytryptophan) travels through the bloodstream to the brain, and crosses the blood-brain barrier. Once in the brain, the 5-HTP can then be converted into Serotonin for use within the brain.
Supplementing the diet with additional L-Tryptophan can increase levels of this neurotransmitter and may counteract deficiency. However, supplementing with 5-HTP has been found more reliable for increasing levels of Serotonin.
In research studies, the use of 5-HTP for the alleviation of depression symptoms has demonstrated comparable effects to the use of some SSRI medications. Clinical trials have hypothesized that by increasing the levels of this neurotransmitter available to activate Serotonin receptors, 5-HTP may be able to improve mild forms of depression, anxiety, and improve sleep quality.
Danger and Contraindications
5-HTP is typically sold in 50 to 100 mg capsules or pills. The recommended dosage is between 50 – 600 mg per day. Speak to your doctor to determine the right dose for you to use.
If you have been diagnosed with a medical condition by your doctor and are currently taking SSRIs, MAOIs, or other types of anti-depressant drugs, do not take 5-HTP. This supplement could interact with other 5-HT receptor antagonists or agonists and negatively impact the outcomes of any medications you are currently using.
L-Tryptophan and 5-HTP supplements may interfere with these drugs and cause unsafe reactions or imbalances in mood. Too much Serotonin can cause a condition known as Serotonin Syndrome in which receptors for this neurotransmitter are over-stimulated.
Signs of this condition include twitching, increased heart rate, shivering, excessive sweating, and dilated pupils. This condition can be fatal in serious cases if it is left untreated.
Increasing Serotonin levels may cause interactions with other medications as well, including some drugs prescribed for heart conditions. It is advised to always consult with your doctor before taking any supplements.
5-HTP and other Serotonin supplements are recommended for short term use and should not be used longer than three months. When used at appropriate dosages for short periods of time, the risk of 5-HTP side effects is relatively low.
- Morrissette DA, Stahl SM. Modulating the serotonin system in the treatment of major depressive disorder. CNS Spectr. 2014
- Howell LL, Cunningham KA. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev. 2015
- Tang H, McGowan OO, Reynolds GP. Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action. Pharmacogenomics. 2014
- Watts SW. Serotonin and sensory nerves: meeting in the cardiovascular system. Vascul Pharmacol. 2014
- Alusik S, Kalatova D, Paluch Z. Serotonin syndrome. Neuro Endocrinol Lett. 2014
- Selvaraj S, Arnone D, Cappai A, Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014
- Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG. Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. CNS Neurosci Ther. 2014
- Fabbri C, Minarini A, Niitsu T, Serretti A. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol. 2014
- Benhamú B, MartÃn-Fontecha M, Vázquez-Villa H, Pardo L, López-RodrÃguez ML. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J Med Chem. 2014
- Dayer A. Serotonin-related pathways and developmental plasticity: relevance for psychiatric disorders. Dialogues Clin Neurosci. 2014
- Ding S, Zhou FM. Serotonin regulation of subthalamic neurons. Rev Neurosci. 2014
- Monti JM, Jantos H. The role of serotonin 5-HT7 receptor in regulating sleep and wakefulness. Rev Neurosci. 2014
- Dussor G. Serotonin, 5HT1 agonists, and migraine: new data, but old questions still not answered. Curr Opin Support Palliat Care. 2014
- Bundeff AW, Woodis CB. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother. 2014
- Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014
- Yang CJ, Tan HP, Du YJ. The developmental disruptions of serotonin signaling may involved in autism during early brain development. Neuroscience. 2014
- Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J. 2014
- Reeves RR, Ladner ME, Smith P. About serotonin syndrome. J Miss State Med Assoc. 2013
- Seyedabadi M, Fakhfouri G, Ramezani V, Mehr SE, Rahimian R. The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Exp Brain Res. 2014
- Mahar I, Bambico FR, Mechawar N, Nobrega JN. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev. 2014
- Uphouse L. Pharmacology of serotonin and female sexual behavior. Pharmacol Biochem Behav. 2014
- Johnston KD, Lu Z, Rudd JA. Looking beyond 5-HT(3) receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting. Eur J Pharmacol. 2014
- Kalbitzer J, Kalbitzer U, Knudsen GM, Cumming P, Heinz A. How the cerebral serotonin homeostasis predicts environmental changes: a model to explain seasonal changes of brain 5-HTT as intermediate phenotype of the 5-HTTLPR. Psychopharmacology (Berl). 2013
- Bijlsma EY, Chan JS, Olivier B, Veening JG, Millan MJ, Waldinger MD, Oosting RS. Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav. 2014
- Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin transporter and serotonin receptors. Handb Exp Pharmacol. 2013
- Hensler JG, Artigas F, Bortolozzi A, Daws LC, De Deurwaerdère P, Milan L, Navailles S, Koek W. Catecholamine/Serotonin interactions: systems thinking for brain function and disease. Adv Pharmacol. 2013
- Haberzettl R, Bert B, Fink H, Fox MA. Animal models of the serotonin syndrome: a systematic review. Behav Brain Res. 2013
- Kato S. Role of serotonin 5-HT₃ receptors in intestinal inflammation. Biol Pharm Bull. 2013
- Siegel JZ, Crockett MJ. How serotonin shapes moral judgment and behavior. Ann N Y Acad Sci. 2013
- Cunningham KA, Anastasio NC. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology. 2014
- Bradley AJ, Lenox-Smith AJ. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. J Psychopharmacol. 2013
- Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013
- Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013
- Gur TL, Kim DR, Epperson CN. Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise. Psychopharmacology (Berl). 2013
- Kuhn M, Popovic A, Pezawas L. Neuroplasticity and memory formation in major depressive disorder: an imaging genetics perspective on serotonin and BDNF. Restor Neurol Neurosci. 2014
- Salomon RM, Cowan RL. Oscillatory serotonin function in depression. Synapse. 2013
- Araragi N, Lesch KP. Serotonin (5-HT) in the regulation of depression-related emotionality: insight from 5-HT transporter and tryptophan hydroxylase-2 knockout mouse models. Curr Drug Targets. 2013
- Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol. 2013
- Catena-Dell'Osso M, Rotella F, Dell'Osso A, Fagiolini A, Marazziti D. Inflammation, serotonin and major depression. Curr Drug Targets. 2013
- Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms--implications of 5-HT₇ and other 5-HT receptor types. Eur J Pharmacol. 2013
- Harrington RA, Lee LC, Crum RM, Zimmerman AW, Hertz-Picciotto I. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 2013
- Blier P, El Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci. 2013
- Pringle A, McCabe C, Cowen PJ, Harmer CJ. Antidepressant treatment and emotional processing: can we dissociate the roles of serotonin and noradrenaline? J Psychopharmacol. 2013
- Duke AA, Bègue L, Bell R, Eisenlohr-Moul T. Revisiting the serotonin-aggression relation in humans: a meta-analysis. Psychol Bull. 2013
- Baganz NL, Blakely RD. A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci. 2013
- Gupta A, Sharma PK, Garg VK, Singh AK, Mondal SC. Role of serotonin in seasonal affective disorder. Eur Rev Med Pharmacol Sci. 2013
- Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013
- Haleem DJ. Serotonin neurotransmission in anorexia nervosa. Behav Pharmacol. 2012
- Nonogaki K. Serotonin conflict in sleep-feeding. Vitam Horm. 2012
- Maron E, Nutt D, Shlik J. Neuroimaging of serotonin system in anxiety disorders. Curr Pharm Des. 2012
- Berumen LC, RodrÃguez A, Miledi R, GarcÃa-Alcocer G. Serotonin receptors in hippocampus. ScientificWorldJournal. 2012
- Dalley JW, Roiser JP. Dopamine, serotonin and impulsivity. Neuroscience. 2012
- Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012
- Cirillo C, Vanden Berghe P, Tack J. Role of serotonin in gastrointestinal physiology and pathology. Minerva Endocrinol. 2011
- Kiser D, Steemers B, Branchi I, Homberg JR. The reciprocal interaction between serotonin and social behaviour. Neurosci Biobehav Rev. 2012
- Sadler TW. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. Reprod Toxicol. 2011
- Ciarleglio CM, Resuehr HE, McMahon DG. Interactions of the serotonin and circadian systems: nature and nurture in rhythms and blues. Neuroscience. 2011
- Fernandez SP, Gaspar P. Investigating anxiety and depressive-like phenotypes in genetic mouse models of serotonin depletion. Neuropharmacology. 2012
- Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer's disease: a new therapeutic target? CNS Drugs. 2011
- Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol. 2011
- Homberg JR. Serotonin and decision making processes. Neurosci Biobehav Rev. 2012
- Watanabe H, Rose MT, Aso H. Role of peripheral serotonin in glucose and lipid metabolism. Curr Opin Lipidol. 2011
- Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011
- Meneses A, Perez-Garcia G, Ponce-Lopez T, Tellez R, Castillo C. Serotonin transporter and memory. Neuropharmacology. 2011
- Olivier JD, Blom T, Arentsen T, Homberg JR. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Prog Neuropsychopharmacol Biol Psychiatry. 2011
Article last updated on: March 25th, 2018 by Nootriment